Positive outcomes for iSTAR Medical’s MIGS MINIject shown in trials of over 130 glaucoma patients

29 September 2020

Pooled data confirm excellent safety and efficacy profile with very low rate of reintervention Wavre, Belgium: 29 September 2020 – iSTAR Medical, a medtech company developing minimally invasive ophthalmic implants for powerful, safe and enduring treatment of patients with glaucoma, announced today that its micro-invasive glaucoma surgery (MIGS) device MINIjectTM showed consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. The pooled analysis reviewed data from over 130 patients implanted with MINIject into the supraciliary space in stand-alone procedures across 11 trial sites in Europe, the Americas and Asia. The final two-year data from the STAR-I trial and the six-month follow-up data from the STAR-II European trial, which are comprised in the pooled analysis, will both be presented at the upcoming European Society of Cataract and Refractive Surgery (ESCRS) meeting on October 2-4. The six-month primary endpoint results from the STAR-II trial of MINIject have recently been published in the peer-reviewed Journal of Glaucoma, the official publication of the World Glaucoma Association.

More info on iSTAR Medical's website